V P Matei1,2, A Mihailescu1,2, G Paraschiv3, R Al-Bataineh1, T Purnichi1. 1. "Prof. Dr. Alexandru Obregia" Clinical Psychiatric Hospital, Bucharest, Romania. 2. "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 3. University of Medicine and Pharmacy, Craiova, Psychiatry Department, Craiova, Romania.
Abstract
CONTEXT: Schizophrenia is a chronic disease most frequently necessitating lifelong antipsychotic treatment. Selecting which antipsychotic is to be prescribed in an individual schizophrenia patient represents an important clinical decision that need to take into account efficacy and side effects. OBJECTIVE: Evaluating weight gain related with one year antipsychotic treatment in antipsychotic naive first-episode schizophrenia patients. DESIGN: This study is an analysis of weight gain associated with typical or atypical antipsychotics used in European First Episode Schizophrenia Trial (EUFEST) study. SUBJECTS AND METHODS: 113 first episode naïve antipsychotic schizophrenia patients included in EUFEST - Romanian cohort, who were randomized to one of the 5 treatment arms. Weight was obtained at baseline, 3, 6, 9 and 12 months for the 5 antipsychotics (typical-Haloperidol; atypical-Olanzapine, Amisulpride, Ziprasidone, Quetiapine). RESULTS: There are no statistically significant differences between groups treated with typical or atypical antipsychotics or between any individual antipsychotics concerning weight gain during the study. Weight gain was the highest in the first 3 months (57.49%) for all the studied neuroleptics. At the end of the study, the less increase was observed with ziprasidone (3.87 kg) and the highest with olanzapine (9.83 kg). CONCLUSION: Increase in weight has taken place for each individual neuroleptic, but also as a group (all neuroleptics) in the first three months (57.49%). Therefore, we should address the issue of weight gain with great care, especially in first period of antipsychotic administration, in order to fast deploy intervention tailored to maintain pre-treatment weight.
CONTEXT: Schizophrenia is a chronic disease most frequently necessitating lifelong antipsychotic treatment. Selecting which antipsychotic is to be prescribed in an individual schizophrenia patient represents an important clinical decision that need to take into account efficacy and side effects. OBJECTIVE: Evaluating weight gain related with one year antipsychotic treatment in antipsychotic naive first-episode schizophrenia patients. DESIGN: This study is an analysis of weight gain associated with typical or atypical antipsychotics used in European First Episode Schizophrenia Trial (EUFEST) study. SUBJECTS AND METHODS: 113 first episode naïve antipsychotic schizophrenia patients included in EUFEST - Romanian cohort, who were randomized to one of the 5 treatment arms. Weight was obtained at baseline, 3, 6, 9 and 12 months for the 5 antipsychotics (typical-Haloperidol; atypical-Olanzapine, Amisulpride, Ziprasidone, Quetiapine). RESULTS: There are no statistically significant differences between groups treated with typical or atypical antipsychotics or between any individual antipsychotics concerning weight gain during the study. Weight gain was the highest in the first 3 months (57.49%) for all the studied neuroleptics. At the end of the study, the less increase was observed with ziprasidone (3.87 kg) and the highest with olanzapine (9.83 kg). CONCLUSION: Increase in weight has taken place for each individual neuroleptic, but also as a group (all neuroleptics) in the first three months (57.49%). Therefore, we should address the issue of weight gain with great care, especially in first period of antipsychotic administration, in order to fast deploy intervention tailored to maintain pre-treatment weight.
Entities:
Keywords:
antipsychotics; schizophrenia; weight gain
Authors: Joseph P McEvoy; Jonathan M Meyer; Donald C Goff; Henry A Nasrallah; Sonia M Davis; Lisa Sullivan; Herbert Y Meltzer; John Hsiao; T Scott Stroup; Jeffrey A Lieberman Journal: Schizophr Res Date: 2005-08-30 Impact factor: 4.939
Authors: D A Wirshing; W C Wirshing; L Kysar; M A Berisford; D Goldstein; J Pashdag; J Mintz; S R Marder Journal: J Clin Psychiatry Date: 1999-06 Impact factor: 4.384